Clinical Trials
3 trialsNCT04398524 2024-01-16
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT03669718 2023-12-29
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown